New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
12:14 EDTZIOPZiopharm confirms PFS is endpoint in palifosfamide trial, Feuerstein says
Ziopharm confirmed that progression-free survival, or PFS, is now an acceptable endpoint for approval in palifosfamide's Phase III trial, The Street's Adam Feuerstein said via Twitter, citing a company spokesperson. Shares of Ziopharm are up 5% to $5.53 in early afternoon trading.
News For ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
07:10 EDTZIOPZIOPHARM says first patient enrolled in Phase 1 study of CAR T-Cell therapy
ZIOPHARM Oncology (ZIOP) announced that the first patient has been enrolled in a Phase 1 clinical study of its second generation non-viral CD19-specific chimeric antigen receptor modified T-cell therapy in patients with advance lymphoid malignancies. The CD19-specific T cells were modified using the Sleeping Beauty system to stably express the CAR in T cells. The Sleeping Beauty transposon-transposase is a unique non-viral system for introducing genes encoding CARs and T-cell receptors into lymphocytes and is exclusively licensed by Intrexon Corporation (XON) through The University of Texas MD Anderson Cancer Center and accessed as part of ZIOPHARM's collaboration.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use